Skip to main content

Advertisement

Table 2 Drug resistance mutations (DRMs) of participants tested for drug resistance among those with HIV viral loads ≥1000 copies/ml at enrolment, by ARV class

From: From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults

Drug resistance mutation(s) Proportion with amplified drug resistance tests, n (%) Proportion with major PI mutations, n (%)1 Most common mutations2
All 110 7 (6.4)  
No mutation detected 8 (7.3)   
At least one detected (NRTI, NNRTI, PI) 102 (92.7) 7 (6.9)  
Any NRTI 92 (83.6) 6 (6.5) Non-TAMs: M184V (20.7%), K65R (8.0%) TAMs: M41L (8.0%), K70R (8.0%)
Any NNRTI 77 (70.0) 4 (5.2) K103N (19.0%), G190A (7.0%), Y181C (6.0%)
Any PI3 33 (30.0) 7 (21.2) Major: V82A (7.0%) and I54V, M46I, L33I (all 5.0%) Accessory: L10I (27.0%), L10V (12.0%), L10F(5.0%)
Mutation to 1 ARV class only (n = 22)  
NRTI 14 (12.7) 0 (0.0)
NNRTI 7 (6.4) 0 (0.0)
PI 1 (0.9) 0 (0.0)
Mutation to 2 ARV classes only (n = 60)
NRTI + NNRTI 48 (43.6) 0 (0.0)
PI + NRTI 10 (9.1) 3 (30.0)
PI + NNRTI 2 (1.8) 1 (50.0)
Mutations to 3 ARV classes (n = 20) 4 20 (18.2) 3 (15.0)
HIV subtype
A 37 (33.6) 3 (8.1) V82A/S, I54V/U, M46I/L, K43T, L10F, L89V, L24IL
B 5 (4.5) 0 (0.0)  
C 6 (5.5) 0 (0.0)  
D 38 (34.5) 4 (10.5) V82A/V/F, I54IV, I54V, M46I, L33F, L10I, L10F, L24I, K20T, A71T, Q58E, I47V
CRF01_AE 24 (21.8) 0 (0.0)  
  1. TAMs thymidine analogue mutations
  2. 1These are row percentages of participants with major PI mutations in each category with amplified drug resistance tests
  3. 2Denominator is all mutations to NRTI (n = 352), NNRTI (n = 144) or PI (n = 59)
  4. 3PI DRMs include 7 with a major and 26 with only minor PI DRMs
  5. 4Only major PI mutations are shown for HIV subtypes